Riskpilot← Back to searchSign inGet full accessSixera Pharma AB
ABActiveOrg 5569014763Skeppsbron 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20120 employees
Revenue 2024
SEK 0
EBITDA margin
—
-1% vs 2023
Equity ratio
61.5%
Financial strength
Net profit 2024
SEK -7,2M
0% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -7,2M | -1% |
| Net profit | SEK -7,2M | +0% |
| Total assets | SEK 4,8M | -33% |
| Equity | SEK 3M | -37% |
| Employees | 0 | — |
Legal name
Sixera Pharma AB
Org number
5569014763
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 augusti 2012
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Hansson, Stig Lennart i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva verksamhet bestående i forskning, utveckling och kommersialisering av läkemedel samt därmed förenlig verksamhet.
Address
Skeppsbron 16
Email
dechateau@sixerapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −384 | −960 | −2 558 | −7 891 | −3 125 | −3 784 | −10 359 | −9 235 | −7 142 | −7 186 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −384 | −960 | −2 558 | −7 891 | −3 125 | −3 784 | −10 359 | −9 235 | −7 142 | −7 186 |
| Net financials | — | — | — | −9 | −10 | −1 | −20 | −16 | — | 13 |
| Profit before tax | −384 | −960 | −2 558 | −7 900 | −3 135 | −3 785 | −10 379 | −9 252 | −7 142 | −7 173 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −384 | −960 | −2 558 | −7 900 | −3 135 | −3 785 | −10 379 | −9 252 | −7 142 | −7 173 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 683 | 1 139 | 8 997 | 8 477 | 4 365 | 25 331 | 17 208 | 7 428 | 7 162 | 4 818 |
| Equity | 421 | 281 | 7 735 | 6 335 | 3 200 | 24 461 | 14 082 | 4 830 | 4 687 | 2 964 |
| Long-term debt | 55 | 436 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 |
| Short-term debt | 207 | 422 | 762 | 1 642 | 665 | 371 | 2 626 | 2 098 | 1 975 | 1 355 |
| Total debt | 262 | 858 | 1 262 | 2 142 | 1 165 | 871 | 3 126 | 2 598 | 2 475 | 1 855 |
EBITDA margin
-718600000.0%
This company
15.8%
Market median
-4548101366% vs market
20152024
Equity ratio
61.5%
This company
38.2%
Market median
+61% vs market
20152024
Return on equity
-242.0%
This company
18.4%
Market median
-1415% vs market
20152024
Net profit margin
-717300000.0%
This company
8.1%
Market median
-8855555656% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.63×
This company
0.62×
Market median
+2% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FP Audit | Audit | 2022 | — | — |
BP Audit | Audit | 2020 | — | — |
MD Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sixera Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Filip Patrik Laurin | Audit | 0 companies |
| Bengt Peter Eriksson | Audit | 0 companies |
| Maarten De Chateau | Chief Executive Officer | 0 companies |
| Stig Lennart Hansson | Chairman | 0 companies |
| Thomas Bengt Eldered | Board of Directors | 0 companies |
| E E Cecilia Stureborg von Schéele | Board of Directors | 0 companies |
| Karl Ola Elmqvist | Board of Directors | 0 companies |
| Karl Johan Torbjörn Egelrud | Board of Directors | 0 companies |
| Margit Mahlapuu | Board of Directors | 0 companies |
| Roger William Gunnarsson | Board of Directors | 0 companies |